Life-Threatening Allergies: Using a Patient-Engaged Approach.

Background: Adolescents at risk for anaphylaxis are a growing concern. Novel training methods are needed to better prepare individuals to manage anaphylaxis in the community.

Introduction: Didactic training as the sole method of anaphylaxis education has been shown to be ineffective.

Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age.

Background: Hizentra® (IGSC 20%) is a 20% liquid IgG product approved for subcutaneous administration in adults and children 2 years of age and older who have primary immunodeficiency disease (PIDD). There is limited information about the use of IGSC 20 % in very young children including those less than 5 years of age.

Methods: A retrospective chart review involved 88 PIDD infants and children less than 5 years of age who received Hizentra®.

Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.

Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective.